Tabular foundation models are the next major unlock for AI adoption, especially in industries sitting on massive databases of ...

The following information was released by the Federal Reserve Bank of Atlanta:. In preparation for FOMC meetings, policymakers have the Fed Board staff projection of this "advance" estimate at their ...

MESCIUS USA, Inc., a global provider of award-winning enterprise software development tools, is pleased to announce the Spread.NET v19 release. This latest update delivers significant new enhancements ...

Make Gemini work inside your spreadsheets: subscribe to the newsletter for tested prompts, ready-made table and chart ...

Microsoft's spreadsheet program can do way more than you might imagine. These are the hacks and tricks you need to know.

Market breadth and risk appetite offer early clues as the bull market enters a mature phase Key intermarket ratios reveal where leadership may emerge—or fade—heading into the new year From US equities ...

Knowledge graphs are a powerful tool for bringing together information from biological databases and linking what is already known about genes, diseases, treatments, molecular pathways and symptoms in ...

As many market participants anticipate a year-end rally, there are mounting indications that such an outcome is far from assured. Investor positioning appears increasingly stretched, with multiple ...

OpenAI’s latest valuation round pegged the company at roughly $500 billion, making it perhaps the most valuable startup in Silicon Valley and one of the most valuable privately held companies in the ...

The New York Mets saw a chance to add an intriguing player, and they got rid of a pitcher to do it. The tandem moves came Wednesday, announced by the team. The Mets have claimed catcher Drew Romo off ...

ORLANDO, Fla. — Pete Alonso isn’t the first power-hitting first baseman in his early 30s the Orioles have signed to a nine-figure deal. The Orioles are still feeling the effects of the disastrous ...

Epcoritamab addition to R2 significantly improves progression-free survival and overall response rates in relapsed follicular lymphoma. The EPCORE FL-1 trial results show a 79% progression-free ...